- ECONOMIC IMPACT -

Latest update: 28 February 2022

Swift development of COVID-19 vaccines and strong capital markets continue to drive Pharma growth.

Asian nations top GlobalData’s COVID-19 economic recovery scorecard.

4.4%

The consensus forecast for world GDP growth in 2022 is 4.4%.

COVID-19

GlobalData polls show that concern over the spread of COVID-19 remains volatile, as does business optimism.

Momentum of Global Economic Growth to Weaken in 2022 Amid Uncertainty

- SECTOR IMPACT: PHARMA -

Latest update: 2 February 2022

industry development

Developers with COVID-19 therapies and vaccines will benefit in the short-term, as intense investor interest will drive up stock prices and provide these companies with cash and resources to further pipeline development.

In Q1 2020 Bio/Pharma companies with a COVID-19 drug in the pipeline saw a smaller decrease in market cap than companies without a COVID-19 drug in the pipeline.

Outsourcers

Stalled clinical trials created a work vacuum for CROs and CDMOs but disrupted trials are slowly starting to resume. CMOs and Excess Capacity Contract Manufacturers with secure supply lines will benefit from short term boost in generic drugs manufacturing needed to treat COVID patients. Outsourcing partners must deal with issues surrounding a potential excess of client needs upon initiation of future trials, with guidance from regulatory agencies still pending.

Key Market Pharma Developments

PAYERS


Currently, payers are experiencing pressure to reimburse ICU care and eventually this could expand to include potentially expensive and unproven drugs if there is a suggestion that they might be effective in treating COVID-19. In addition, payer plans have evolved to include reimbursement of telemedicine as providers began to rely on this service during the pandemic. Reimbursement of telemedicine is likely here to stay.


PROVIDERS


Hospitals are being forced to operate with a shortage of proper personal protection equipment, complicating the health and safety of both patients and staff, while outpatient healthcare providers will have to rely on telemedicine and remote methods of treating patients which may be less effective than face-to-face patient management.

Share this article

Go to article: Home | Two years of Covid-19Go to article: In this issueGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: CSafe GlobalGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Controlant Company InsightGo to article: ControlantGo to article: Contract Pharmaceuticals Limited CanadaGo to article: CommentGo to article: Ukraine: Russian invasion could cause spike in Covid-19 cases Go to article: First vaccines, now drugs: FDA’s second wave of emergency Covid-19 approvalsGo to article: International Women’s Day spotlight: endometriosisGo to article: Remote audits – stopgap measure or the new normal?Go to article: Owen Mumford Company Insight Go to article: Owen MumfordGo to article: BaxterGo to article: In DepthGo to article: Two years of Covid-19: lessons the pandemic taught about delivering essential vaccinesGo to article: A perfect storm: Covid-19 viral vector manufacturing adds further burden to CAR-Go to article: Russia sanctions: what next for Sputnik Covid-19 vaccine production around the wGo to article: Profit for patients: can NFTs allow people to monetise their health data?Go to article: Navigating distribution challenges for rare disease drugsGo to article: NiproGo to article: Datwyler Company InsightGo to article: DatwylerGo to article: In DataGo to article: North America is seeing a hiring boom in pharma digital media rolesGo to article: Filings buzz: 23% increase in industrial automation mentions in Q3 of 2021Go to article: Event: Outsourcing in Clinical Trials Europe 2022Go to article: EventsGo to article: Next issue